Healthcare

Personalis develops advanced cancer sequencing and blood-based monitoring tools, with NeXT Personal at the center of its growth effort. The company operates in a promising oncology niche, and recent commercial momentum has put its platform potential back in focus.

Pennant Group runs home health, hospice, and senior living operations, with most revenue tied to care delivered outside hospitals. Rapid revenue expansion, improving cash flow, and exposure to aging-population demand make it a company worth a closer look.

Progyny provides employer-focused fertility and women’s health benefits through a specialized, asset-light platform. Strong cash flow, low debt, and solid profitability make it a notable healthcare name as it works to expand beyond its core fertility niche.

P3 Health Partners coordinates care for Medicare Advantage members through a value-based model built around physician networks and recurring payer revenue. The appeal lies in its exposure to a growing senior-care market and the potential for better margins if execution improves.

ORIC Pharmaceuticals is developing cancer medicines aimed at overcoming treatment resistance, a large and medically important area in oncology. Its focused pipeline and very low debt stand out, while future value depends mainly on clinical milestones and execution.